{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T01:37:20Z","timestamp":1786412240196,"version":"build-2736575974"},"update-to":[{"DOI":"10.1002\/14651858.cd007572.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000}}],"reference-count":132,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007572.pub4","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T07:32:17Z","timestamp":1747121537000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Anti-IL-12\/23p40 antibodies for induction of remission in Crohn's disease"],"prefix":"10.1002","volume":"2025","author":[{"given":"Johannes","family":"Hasskamp","sequence":"additional","affiliation":[{"name":"Division of Epidemiology and Biometry; Carl von Ossietzky University of Oldenburg; Oldenburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Meinhardt","sequence":"additional","affiliation":[{"name":"Klinikum Oldenburg A\u00d6R, University Clinic for Internal Medicine - Gastroenterology; Oldenburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Timmer","sequence":"additional","affiliation":[{"name":"Division of Epidemiology and Biometry; Carl von Ossietzky University of Oldenburg; Oldenburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"issue":"8","key":"10.1002\/14651858.CD007572.pub4-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1093\/ecco-jcc\/jjad047","article-title":"A phase 2b, randomised, double-blind, placebo-controlled, parallel-arm, multicenter study evaluating the safety and efficacy of tesnatilimab in patients with moderately to severely active Crohn's disease","volume":"17","author":"Allez","year":"2023","journal-title":"Journal of Crohn's & Colitis"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD007572.pub4-BIB0002|cit2","first-page":"S408","article-title":"Pharmacokinetics and exposure-response relationships of ustekinumab during IV induction and SC maintenance treatment of patients with Crohn's disease with ustekinumab: Results from the UNITI-1, UNITI-2, and IM-UNITI studies","volume":"150","author":"Adedokun","year":"2016","journal-title":"Gastroenterology"},{"issue":"20","key":"10.1002\/14651858.CD007572.pub4-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's disease","volume":"375","author":"Feagan","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD007572.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"S377","DOI":"10.1016\/S0016-5085(16)31326-9","article-title":"Molecular response to ustekinumab in moderate-to-severe Crohn's disease by serum protein analysis: Results from UNITI-1 induction, UNITI-2 induction, and IMUNITI maintenance studies","volume":"150","author":"Li","year":"2016","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007572.pub4-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/MIB.0000000000000720","article-title":"A multicenter, double-blind, placebo-controlled phase 3 study of ustekinumab, a human IL-12\/23P40 mAB, in moderate to severe Crohn's disease refractory to anti-TFNalpha: UNITI-1","volume":"22","author":"Sandborn","year":"2016","journal-title":"Inflammatory Bowel Diseases"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD007572.pub4-BIB0006|cit6","first-page":"S982","article-title":"Assessment of serum C-reactive protein, fecal lactoferrin, and fecal calprotectin in patients with moderate-severely active Crohns disease: Results from the IM UNITI maintenance study","volume":"150","author":"Sandborn","year":"2016","journal-title":"Gastroenterology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD007572.pub4-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"S1004","DOI":"10.1016\/S0016-5085(16)33398-4","article-title":"Ustekinumab improves general health status and disease-specific health related quality of life of patients with moderate to severe Crohn's disease: Results from the UNITI and IMUNITI phase 3 clinical trials","volume":"150","author":"Sands","year":"2016","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD007572.pub4-BIB0008|cit8","first-page":"563","article-title":"A multicenter, double-blind, placebo-controlled pH3 study of ustekinumab, a human monoclonal antibody to IL-12\/23p40, in patients with moderately-severely active Crohn's disease who are not naive or not refractory to anti-TNFa: UNITI-2","volume":"3","author":"Feagan","year":"2015","journal-title":"United European Gastroenterology Journal"},{"issue":"6","key":"10.1002\/14651858.CD007572.pub4-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1016\/S0016-5085(20)31008-8","article-title":"615: Pharmacokinetics of ustekinumab in children and adolescents with moderately to severely active Crohn's disease: Results from UniStar, a phase 1 study","volume":"158","author":"Adedokun","year":"2020","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1002\/14651858.CD007572.pub4-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1093\/ecco-jcc\/jjab089","article-title":"Ustekinumab in paediatric patients with moderately to severely active Crohn's disease: Pharmacokinetics, safety, and efficacy results from UniStar, a Phase 1 study","volume":"15","author":"Rosh","year":"2021","journal-title":"Journal of Crohn's & Colitis"},{"issue":"5","key":"10.1002\/14651858.CD007572.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"S235","DOI":"10.1016\/S0016-5085(20)31274-9","article-title":"1164: Efficacy, safety, tolerability of ustekinumab in pediatric patients with moderately to severely active Crohn's disease: Results from UniStar, a phase 1 study","volume":"158","author":"Rosh","year":"2020","journal-title":"Gastroenterology"},{"issue":"Supp 1","key":"10.1002\/14651858.CD007572.pub4-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1097\/00054725-200802001-00032","article-title":"A multicenter, randomized, phase 2A study of human monoclonal antibody to IL- 12\/23P40 (CNTO 1275) in patients with moderately to severely active Crohn\u2019s disease","volume":"14","author":"Sandborn","year":"2008","journal-title":"Inflammatory Bowel Diseases"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD007572.pub4-BIB0013|cit13","first-page":"A51","article-title":"A multicenter, randomized, phase 2a study of human monoclonal antibody to IL-12\/23p40 (CNTO 1275) in patients with moderately to severely active Crohn's disease","volume":"132","author":"Sandborn","year":"2007","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD007572.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","article-title":"A randomized trial of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease","volume":"135","author":"Sandborn","year":"2008","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1002\/14651858.CD007572.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1038\/ajg.2009.454","article-title":"Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease","volume":"104","author":"Toedter","year":"2009","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD007572.pub4-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(15)32426-4","article-title":"The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the CERTIFI study","volume":"148","author":"Ding","year":"2015","journal-title":"Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD007572.pub4-BIB0017|cit17","first-page":"A133","article-title":"The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the CERTIFI study","volume":"3","author":"Ding","year":"2015","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD007572.pub4-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"S","DOI":"10.14309\/00000434-201110002-01227","article-title":"A multicenter, randomized, double-blind, placebo-controlled phase 2B study of ustekinumab, a human monoclonal antibody to IL-12\/23P40, in patients with moderately to severely active Crohn's disease: Results through week 36 from the CERTIFI trial","volume":"106","author":"Feagan","year":"2011","journal-title":"American Journal of Gastroenterology"},{"issue":"Supp 1","key":"10.1002\/14651858.CD007572.pub4-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1016\/S1873-9946(12)60320-1","article-title":"Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled Phase2b study of ustekinumab in patients with moderately to severely active Crohn's disease","volume":"6","author":"Feagan","year":"2012","journal-title":"Journal of Crohn's & Colitis"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD007572.pub4-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"S231","DOI":"10.1016\/S0016-5085(13)60817-3","article-title":"Assessment of sleep impairment in patients with Crohn's disease: Results from the ustekinumab CERTIFI study","volume":"144","author":"Gasink","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD007572.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"S","DOI":"10.14309\/00000434-201410002-01679","article-title":"Evaluation of an interim Crohn's disease outcome measure (PRO-2) based on 2 patient-reported components (stool frequency, abdominal pain) of the Crohn's disease activity index (CDAI) in the ustekinumab CERTIFI study","volume":"109","author":"Gasink","year":"2014","journal-title":"American Journal of Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD007572.pub4-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(11)60443-5","article-title":"A multicenter, randomized, double-blind, placebo-controlled Phase2b study of ustekinumab, a human monoclonal antibody to IL-12\/23p40, in patients with moderately to severely active Crohn's disease: Results through week 22 from the CERTIFI trial","volume":"140","author":"Sandborn","year":"2011","journal-title":"Gastroenterology"},{"issue":"16","key":"10.1002\/14651858.CD007572.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn's disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007572.pub4-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1097\/00054725-201112002-00076","article-title":"Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled phase2b study of Ustekinumab in patients with moderately to severely active Crohn's disease","volume":"17","author":"Sands","year":"2011","journal-title":"Inflammatory Bowel Diseases"},{"issue":"5","key":"10.1002\/14651858.CD007572.pub4-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(11)61056-1","article-title":"Reductions in fecal calprotectin and lactoferrin following ustekinumab induction therapy in patients with moderate to severe Crohn's disease who have previously failed or been intolerant of TNF antagonist therapies","volume":"140","author":"Toedter","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD007572.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"S344","DOI":"10.14309\/01.ajg.0000776524.51669.ed","article-title":"S748: Early PRO-2 symptom remission following guselkumab induction treatment: Results through week 12 of the phase 2 GALAXI 1 study","volume":"116","author":"Afzali","year":"2021","journal-title":"American Journal of Gastroenterology"},{"issue":"Supplement_1","key":"10.1002\/14651858.CD007572.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"i026","DOI":"10.1093\/ecco-jcc\/jjab232.023","article-title":"OP24: Clinical efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohn's Disease: Week 48 analyses from the phase 2 GALAXI 1 study","volume":"16","author":"Danese","year":"2022","journal-title":"Journal of Crohn's & Colitis"},{"issue":"S3","key":"10.1002\/14651858.CD007572.pub4-BIB0028|cit28","first-page":"169","article-title":"18: Effect of guselkumab induction therapy on endoscopic outcome measures in patients with moderately to severely active Crohn's disease: Week 12 results from the Phase 2 GALAXI 1 study","volume":"36","author":"Leong","year":"2021","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"7","key":"10.1002\/14651858.CD007572.pub4-BIB0029|cit29","first-page":"S","article-title":"888: Efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohn's disease: Week 48 analyses from the phases 2 GALAXI 1 study","volume":"162","author":"Panaccione","year":"2022","journal-title":"Gastroenterology"},{"issue":"S8","key":"10.1002\/14651858.CD007572.pub4-BIB0030|cit30","first-page":"497","article-title":"P0403: Patient-reported outcomes of response and remission following guselkumab induction treatment measured by the inflammatory bowel disease questionnaire: Results through week 12 of the phase 2 GALAXI study","volume":"9","author":"Pan\u00e9s","year":"2021","journal-title":"United European Gastroenterology Journal"},{"issue":"S8","key":"10.1002\/14651858.CD007572.pub4-BIB0031|cit31","first-page":"496","article-title":"P0402: Early PRO-2 symptom remission following guselkumab induction treatment: Results through week 12 of the phase 2 GALAXI 1 study","volume":"9","author":"Reinisch","year":"2021","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD007572.pub4-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"S400","DOI":"10.14309\/01.ajg.0000776960.58058.bf","article-title":"S857: Patient-reported outcomes of response and remission following guselkumab induction treatment as measured by the inflammatory bowel disease questionnaire: Results through week 12 of the phase 2 GALAXI 1 study","volume":"116","author":"Rubin","year":"2021","journal-title":"American Journal of Gastroenterology"},{"issue":"S8","key":"10.1002\/14651858.CD007572.pub4-BIB0033|cit33","first-page":"64","article-title":"OP089: The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Crohn's disease: Week 12 interim analyses from the phase 2 GALAXI 1 study","volume":"8","author":"Sandborn","year":"2020","journal-title":"United European Gastroentrology Journal"},{"issue":"6","key":"10.1002\/14651858.CD007572.pub4-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1053\/j.gastro.2022.01.047","article-title":"Guselkumab for the treatment of Crohn\u2019s Disease: Induction results from the phase 2 GALAXI-1 study","volume":"162","author":"Sandborn","year":"2022","journal-title":"Gastroenterology"},{"issue":"S3","key":"10.1002\/14651858.CD007572.pub4-BIB0035|cit35","first-page":"108","article-title":"90: Effect of guselkumab induction therapy on inflammatory biomarkers in patients with moderately to severely active Crohn\u2019s disease: Week 12 results from the Phase 2 GALAXI 1 study","volume":"36","author":"Sands","year":"2021","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"S2","key":"10.1002\/14651858.CD007572.pub4-BIB0036|cit36","first-page":"124","article-title":"PP-0132: The effect of guselkumab induction therapy on inflammatory biomarkers in patients with moderately-to-severely active Crohn\u2019s disease: Week 12 results from the phase 2 GALAXI-1 study","volume":"36","author":"Sands","year":"2021","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"7","key":"10.1002\/14651858.CD007572.pub4-BIB0037|cit37","first-page":"S","article-title":"Su1513: Impact of moderate-to-severe endoscopic disease criteria on endoscopic response, endoscopic remission, and deep remission in patients receiving ustekinumab or adalimumab in the SEAVUE study","volume":"162","author":"Allez","year":"2022","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1002\/14651858.CD007572.pub4-BIB0038|cit38","first-page":"1215","article-title":"B15 | The Pharmacokinetics and immunogenicity of ustekinumab and adalimumab in patients with moderate-to-severe Crohn's disease: Results from the SEAVUE study","volume":"9","author":"Danese","year":"2021","journal-title":"United Euopean Gastroenterology Journal"},{"key":"10.1002\/14651858.CD007572.pub4-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"S330","DOI":"10.14309\/01.ajg.0000776424.66172.cb","article-title":"S723: Improvements in work productivity loss and associated cost reductions with ustekinumab and adalimumab in biologic-na\u00efve patients with moderately-to-severely active Crohn\u2019s disease: Results from the SEAVUE study","volume":"116","author":"Ding","year":"2021","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD007572.pub4-BIB0040|cit40","first-page":"S395","article-title":"S851: Health-related quality of life with ustekinumab vs adalimumab for induction and maintenance therapy in biologic-naive patients with moderate-to-severe Crohn\u2019s disease: PROMIS-29 in the SEAVUE study","volume":"116","author":"Lewis","year":"2021","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD007572.pub4-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"S394","DOI":"10.14309\/01.ajg.0000776612.28121.af","article-title":"S770: Health-related quality of life with ustekinumab vs adalimumab for induction and maintenance therapy in biologic-naive patients with moderate-to-severe Crohn\u2019s disease: IBDQ in the SEAVUE study","volume":"116","author":"Loftus","year":"2021","journal-title":"American Journal of Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD007572.pub4-BIB0042|cit42","first-page":"S","article-title":"Tu1445: Effect of pharmacokinetics and immunogenicity on clinical and endoscopic efficacy in patients with moderately-to-severely active Crohn's disease: Results from the SEAVUE study","volume":"162","author":"Panaccione","year":"2022","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD007572.pub4-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1053\/j.gastro.2021.06.040","article-title":"775d: Ustekinumab versus adalimumab for induction and maintenance therapy in moderate-to-severe Crohn\u2019s disease: The SEAVUE study","volume":"161","author":"Sands","year":"2021","journal-title":"Gastroenterology"},{"issue":"10342","key":"10.1002\/14651858.CD007572.pub4-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","article-title":"Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn\u2019s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial","volume":"399","author":"Sands","year":"2022","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD007572.pub4-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(22)61851-1","article-title":"Mo1479: Perianal fistula closure in patients with receiving ustekinumab: Results from the SEAVUE and STARDUST trials","volume":"162","author":"Sands","year":"2022","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD007572.pub4-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(21)02368-4","article-title":"Su446: Pharmacokinetics, immunogenicity, and exposure-response reationship of ustekinumab in patients with Crohn's disease: Results from the week 16 interim analysis of the STARDUST study","volume":"160","author":"D'Haens","year":"2021","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD007572.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S2468-1253(21)00474-X","article-title":"Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial","volume":"7","author":"Danese","year":"2022","journal-title":"Lancet Gastroenterology & Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD007572.pub4-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(21)01686-3","article-title":"Sa073: Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: Results from a week 16 interim analysis of the STARDUST trial","volume":"160","author":"Danese","year":"2021","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD007572.pub4-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(20)33651-9","article-title":"Tu1864: Endoscopic response to induction with ustekinumab in Crohn's disease: STARDUST interim analyses","volume":"158","author":"Danese","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD007572.pub4-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cgh.2022.05.055","article-title":"Early ultrasound response and progressive transmural remission after treatment with ustekinumab in Crohn's disease","volume":"21","author":"Kucharzik","year":"2023","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD007572.pub4-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(20)30833-7","article-title":"344: Intestinal ultrasound response and transmural healing after ustekinumab induction in Crohn's disease: Week 16 interim analysis of the STARDUST trial substudy","volume":"158","author":"Kucharzik","year":"2020","journal-title":"Gastroenterology"},{"issue":"Supplement_1","key":"10.1002\/14651858.CD007572.pub4-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"i132","DOI":"10.1093\/ecco-jcc\/jjab232.129","article-title":"DOP90: Efficacy of the treat-to-target approach in modifying disease course with ustekinumab in patients with moderate-to-severe Crohn's Disease: Results from the STARDUST trial","volume":"16","author":"Peyrin-Biroulet","year":"2022","journal-title":"Journal of Crohn's & Colitis"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD007572.pub4-BIB0053|cit53","first-page":"A","article-title":"Pharmacokinetics and exposure-response relationship of ustekinumab, a human monoclonal antibody to interleukin 12\/23 in patients with moderate-to-severe Crohn's disease","volume":"134","author":"Fasanmade","year":"2008","journal-title":"Gastroenterology"},{"issue":"5S","key":"10.1002\/14651858.CD007572.pub4-BIB0054|cit54","first-page":"A3","article-title":"OP006: Exposure-response to sc ustekinumab in moderate-severe Crohn's disease: Results from the IM-UNITI maintenance study","volume":"5","author":"Adedokun","year":"2017","journal-title":"United European Gastroenterology Journal"},{"issue":"Suppl_1","key":"10.1002\/14651858.CD007572.pub4-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"S359","DOI":"10.1093\/ecco-jcc\/jjx002.673","article-title":"P549: Effect of maintenance ustekinumab on corticosteroid-free clinical outcomes in patients with Crohn's disease","volume":"11","author":"Feagan","year":"2017","journal-title":"Journal of Crohn's & Colitis"},{"issue":"20","key":"10.1002\/14651858.CD007572.pub4-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD007572.pub4-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(18)32139-5","article-title":"Su1793: Outcomes of maintenance ustekinumab therapy for Crohn's disease based on inflammatory burden: A post-hoc analysis of the UNITI trials","volume":"154","author":"Feagan","year":"2018","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD007572.pub4-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/ecco-jcc\/jjz110","article-title":"IM-UNITI: Three-year efficacy, safety, and immunogenicity of ustekinumab treatment of Crohn's disease","volume":"14","author":"Hanauer","year":"2020","journal-title":"Journal of Crohn's & Colitis"},{"key":"10.1002\/14651858.CD007572.pub4-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"S303","DOI":"10.14309\/00000434-201610001-00665","article-title":"Different induction response criteria do not influence 1-year response and remission rates of ustekinumab 90 mg Q8w in phase III program","volume":"111","author":"Naessens","year":"2016","journal-title":"American Journal of Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007572.pub4-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"A32","DOI":"10.1136\/gutjnl-2016-312388.5","article-title":"OC-057: A PH3 randomised, multicenter, double-blind, placebo (PBO)-controlled study of ustekinumab (UST) maintenance therapy in moderate-severe Crohn's disease (CD) pts: Results from IM-UNITI","volume":"65","author":"Sandborn","year":"2016","journal-title":"Gut"},{"issue":"Suppl_1","key":"10.1002\/14651858.CD007572.pub4-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1093\/ecco-jcc\/jjx002.009","article-title":"OP010: Long term efficacy and safety of ustekinumab for Crohn's disease: Results from IM-UNITI long-term extension through 2 years","volume":"11","author":"Sandborn","year":"2017","journal-title":"Journal of Crohn's & Colitis"},{"issue":"1","key":"10.1002\/14651858.CD007572.pub4-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/apt.14794","article-title":"Long-term efficacy and safety of ustekinumab for Crohn\u2019s disease through the second year of therapy","volume":"48","author":"Sandborn","year":"2018","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"S8","key":"10.1002\/14651858.CD007572.pub4-BIB0063|cit63","first-page":"A121","article-title":"OP306: Efficacy and safety of ustekinumab for Crohn's disease: Results from IM-UNITI long-term extension through 3 years","volume":"6","author":"Sandborn","year":"2018","journal-title":"United European Gastroenterology Journal"},{"key":"10.1002\/14651858.CD007572.pub4-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"S323","DOI":"10.14309\/01.ajg.0000704628.43493.6d","article-title":"S0645: Efficacy and safety of ustekinumab for Crohn's disease through 5 years: final results from the IM-UNITI long-term extension","volume":"115","author":"Sandborn","year":"2020","journal-title":"American Journal of Gastroenterology"},{"issue":"Supplement_1","key":"10.1002\/14651858.CD007572.pub4-BIB0065|cit65","first-page":"S16","article-title":"P034: Efficacy of ustekinumab in Crohn's disease at maintenance week 56: IM-UNITI study","volume":"25","author":"Sandborn","year":"2019","journal-title":"Inflammatory Bowel Diseases"},{"issue":"154","key":"10.1002\/14651858.CD007572.pub4-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"S377","DOI":"10.1016\/S0016-5085(18)31567-1","article-title":"Sa1743: Reduced rates of Crohn's related surgeries, hospitalizations and alternate biologic initiation with ustekinumab in the IM-UNITI study through 2 years","volume":"6","author":"Sandborn","year":"2018","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007572.pub4-BIB0067|cit67","first-page":"A23","article-title":"OC-045: Efficacy & safety of dose adjustment & delayed response to ustekinumab in moderate-to-severe Crohn's disease patients: Results from IM-UNITI maintenance study","volume":"66","author":"Sands","year":"2017","journal-title":"Gut"},{"key":"10.1002\/14651858.CD007572.pub4-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.14309\/01.ajg.0000703904.93768.fb","article-title":"S0464: Cost reduction associated with improvement in work productivity loss from ustekinumab treatment by disease severity states in Crohn\u2019s disease patients: Results from the IM-UNITI clinical trial","volume":"115","author":"Teeple","year":"2020","journal-title":"American Journal of Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD007572.pub4-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/ibd\/izaa214","article-title":"Body mass index does not impact clinical efficacy of ustekinumab in Crohn's disease: A post hoc analysis of the IM-UNITI trial","volume":"27","author":"Wong","year":"2021","journal-title":"Inflammatory Bowel Diseases"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD007572.pub4-BIB0070|cit70","first-page":"A22","article-title":"Anti-interleukin-12 treats active Crohn's disease","volume":"126","author":"Mannon","year":"2004","journal-title":"Gastroenterology"},{"issue":"20","key":"10.1002\/14651858.CD007572.pub4-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1056\/NEJMoa033402","article-title":"Anti-interleukin-12 antibody for active Crohn's disease","volume":"351","author":"Mannon","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD007572.pub4-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1093\/ibd\/izaa086","article-title":"Endoscopic activity and serum TNF-\u03b1 level at baseline are associated with clinical response to ustekinumab in Crohn\u2019s disease patients","volume":"26","author":"Murate","year":"2020","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1002\/14651858.CD007572.pub4-BIB0073|cit73","unstructured":"A study of JNJ-64304500 as add-on therapy in participants with active Crohn's disease (DUET) https:\/\/clinicaltrials.gov\/study\/NCT04655807"},{"key":"10.1002\/14651858.CD007572.pub4-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"S457","DOI":"10.14309\/00000434-201010001-01245","article-title":"Briakinumab (anti-interleukin 12\/23p40, ABT874) for treatment of Crohn's disease","volume":"105","author":"Panaccione","year":"2010","journal-title":"American Journal of Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD007572.pub4-BIB0075|cit75","first-page":"1329","article-title":"Briakinumab for the treatment of Crohn's disease: results of a randomized trial","volume":"21","author":"Panaccione","year":"2015","journal-title":"Inflammatory Bowel Diseases"},{"issue":"7","key":"10.1002\/14651858.CD007572.pub4-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1002\/ibd.21159","article-title":"Randomized, double-blind, placebo-controlled trial of the oral interleukin-12\/23 inhibitor apilimod mesylate for treatment of active Crohn's disease","volume":"16","author":"Sands","year":"2010","journal-title":"Inflammatory Bowel Diseases"},{"issue":"1S","key":"10.1002\/14651858.CD007572.pub4-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"e783","DOI":"10.1097\/MEG.0000000000002256","article-title":"Re-induction with intravenous ustekinumab after secondary loss of response is a valid optimization strategy in Crohn\u2019s disease","volume":"33","author":"Ten Bokkel Huinink","year":"2021","journal-title":"European Journal of Gastroenterology & Hepatology"},{"key":"10.1002\/14651858.CD007572.pub4-BIB0078|cit78","unstructured":"Ihara Y Kitazono T Therapeutic reactivity of ustekinumab in moderate to severe active stage Crohn's disease https:\/\/www.rctportal.niph.go.jp\/en 2017"},{"key":"10.1002\/14651858.CD007572.pub4-BIB0079|cit79","unstructured":"Rintaro M A comparison between combination therapy of ustekinumab boosted by budesonide and monotherapy of ustekinumab for Crohn's disease. (BUUST) https:\/\/jrct.niph.go.jp\/en-top 2020"},{"key":"10.1002\/14651858.CD007572.pub4-BIB0080|cit80","unstructured":"Ustekinumab in fistulising perianal Crohn's disease (USTAP) https:\/\/clinicaltrials.gov\/study\/NCT04496063"},{"key":"10.1002\/14651858.CD007572.pub4-BIB0081|cit81","unstructured":"Study comparing intravenous (IV)\/subcutaneous (SC) risankizumab to IV\/SC ustekinumab to assess change in Crohn's disease activity index (CDAI) in adult participants with moderate to severe Crohn's disease (CD) (SEQUENCE) https:\/\/clinicaltrials.gov\/study\/NCT04524611"},{"key":"10.1002\/14651858.CD007572.pub4-BIB0082|cit82","unstructured":"Induction optimization with Stelara for Crohn's disease https:\/\/clinicaltrials.gov\/study\/NCT04629196"},{"key":"10.1002\/14651858.CD007572.pub4-BIB0083|cit83","unstructured":"PATHFINDER: Evaluating the optimal first-line treatment strategy for moderate-to-severely active ileal-dominant Crohn's disease https:\/\/clinicaltrials.gov\/study\/NCT05928039"},{"issue":"11","key":"10.1002\/14651858.CD007572.pub4-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"e48338","DOI":"10.7759\/cureus.48338","article-title":"Safety and efficacy of biologic therapies (ustekinumab and vedolizumab) in the treatment of inflammatory bowel disease (IBD): A systematic review","volume":"15","author":"Ashraf","year":"2023","journal-title":"Cureus"},{"issue":"11","key":"10.1002\/14651858.CD007572.pub4-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph16111581","article-title":"The efficacy and safety of biologic drugs in the treatment of moderate-severe Crohn's disease: A systematic review","volume":"16","author":"Avedillo-Salas","year":"2023","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"issue":"2","key":"10.1002\/14651858.CD007572.pub4-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1136\/gutjnl-2022-328052","article-title":"Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn's disease: Systematic review and network meta-analysis","volume":"72","author":"Barberio","year":"2023","journal-title":"Gut"},{"issue":"1","key":"10.1002\/14651858.CD007572.pub4-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD007572.pub4-BIB0088|cit88","unstructured":"Covidence Veritas Health Innovation 2022"},{"key":"10.1002\/14651858.CD007572.pub4-BIB0089|cit89","unstructured":"European Medicines Agency Ozespa: Withdrawal of the marketing authorisation application https:\/\/www.ema.europa.eu\/en\/medicines\/human\/withdrawn-applications\/ozespa"},{"key":"10.1002\/14651858.CD007572.pub4-BIB0090|cit90","unstructured":"European Medicines Agency Stelara https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/stelara"},{"key":"10.1002\/14651858.CD007572.pub4-BIB0091|cit91","unstructured":"European Medicines Agency Skyrizi https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/skyrizi"},{"issue":"5","key":"10.1002\/14651858.CD007572.pub4-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s40272-023-00586-7","article-title":"Effectiveness and safety of ustekinumab for pediatric inflammatory bowel disease: A systematic review","volume":"25","author":"Fang","year":"2023","journal-title":"Pediatric Drugs"},{"key":"10.1002\/14651858.CD007572.pub4-BIB0093|cit93","unstructured":"Stelara https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/761044Orig1s000TOC.cfm"},{"issue":"7","key":"10.1002\/14651858.CD007572.pub4-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","article-title":"AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease","volume":"160","author":"Feuerstein","year":"2021","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1002\/14651858.CD007572.pub4-BIB0095|cit95","first-page":"656","article-title":"Etiology and management of lack or loss of response to anti-tumor necrosis factor therapy in patients with inflammatory bowel disease","volume":"15","author":"Fine","year":"2019","journal-title":"Gastroenterology & Hepatology"},{"issue":"7","key":"10.1002\/14651858.CD007572.pub4-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"1091\u20131101","DOI":"10.1093\/ecco-jcc\/jjae013","article-title":"Safety of ustekinumab in inflammatory bowel disease: Pooled safety analysis through 5 years in Crohn's disease and 4 years in ulcerative colitis","volume":"18","author":"Ghosh","year":"2024","journal-title":"Journal of Crohn's & Colitis"},{"issue":"9664","key":"10.1002\/14651858.CD007572.pub4-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(09)60140-9","article-title":"Ustekinumab, a human interleukin 12\/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial","volume":"373","author":"Gottlieb","year":"2009","journal-title":"Lancet"},{"issue":"7650","key":"10.1002\/14651858.CD007572.pub4-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"9317","key":"10.1002\/14651858.CD007572.pub4-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD007572.pub4-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD007572.pub4-BIB0101|cit101","unstructured":"Higgins JP Deeks JJ Altman DG Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD007572.pub4-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/JIR.S157358","article-title":"Clinical utility of ustekinumab in Crohn's disease","volume":"11","author":"Kotze","year":"2018","journal-title":"Journal of Inflammation Research"},{"issue":"4","key":"10.1002\/14651858.CD007572.pub4-BIB0103|cit103","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG clinical guideline: Management of Crohn's disease in adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD007572.pub4-BIB0104|cit104","unstructured":"Higgins JPT Lasserson T Thomas J Flemyng E Churchill R Standards for the conduct of new Cochrane Intervention Reviews Methodological Expectations of Cochrane Intervention Reviews."},{"issue":"12","key":"10.1002\/14651858.CD007572.pub4-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1016\/j.cgh.2021.10.002","article-title":"Effectiveness of reinduction and\/or dose escalation of ustekinumab in Crohn's disease: A systematic review and meta-analysis","volume":"20","author":"Meserve","year":"2022","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"10114","key":"10.1002\/14651858.CD007572.pub4-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/s0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD007572.pub4-BIB0107|cit107","first-page":"2203","article-title":"Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial","volume":"92","author":"Oren","year":"1997","journal-title":"American Journal of Gastroenterology"},{"issue":"9625","key":"10.1002\/14651858.CD007572.pub4-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"issue":"18","key":"10.1002\/14651858.CD007572.pub4-BIB0109|cit109","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJM198005013021801","article-title":"Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study","volume":"302","author":"Present","year":"1980","journal-title":"New England Journal of Medicine"},{"issue":"17","key":"10.1002\/14651858.CD007572.pub4-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1056\/NEJMoa1010858","article-title":"A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis","volume":"365","author":"Reich","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007572.pub4-BIB0111|cit111","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"issue":"7737","key":"10.1002\/14651858.CD007572.pub4-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(71)90598-8","article-title":"Controlled trial of azathioprine in Crohn's disease","volume":"298","author":"Rhodes","year":"1971","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD007572.pub4-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-020-0156-2","article-title":"Crohn's disease","volume":"6","author":"Roda","year":"2020","journal-title":"Nature Reviews Disease Primers"},{"issue":"13","key":"10.1002\/14651858.CD007572.pub4-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJM199409293311304","article-title":"A comparison of budesonide with prednisolone for active Crohn's disease","volume":"331","author":"Rutgeerts","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD007572.pub4-BIB0115|cit115","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn's disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD007572.pub4-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD007572.pub4-BIB0117|cit117","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn's disease","volume":"357","author":"Schreiber","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007572.pub4-BIB0118|cit118","unstructured":"Schunemann HJ Oxman AD Vist GE Higgins JP Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"issue":"11","key":"10.1002\/14651858.CD007572.pub4-BIB0119|cit119","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1111\/jgh.15992","article-title":"Long-term effectiveness of ustekinumab comparable to antitumor necrosis factor agents in patients with Crohn's disease","volume":"37","author":"Shiga","year":"2022","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"12","key":"10.1002\/14651858.CD007572.pub4-BIB0120|cit120","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S2468-1253(21)00312-5","article-title":"Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis","volume":"6","author":"Singh","year":"2021","journal-title":"Lancet Gastroenterology & Hepatology"},{"issue":"4","key":"10.1002\/14651858.CD007572.pub4-BIB0121|cit121","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.cgh.2022.07.032","article-title":"Comparative risk of serious infections with biologic agents and oral small molecules in inflammatory bowel diseases: A systematic review and meta-analysis","volume":"21","author":"Solitano","year":"2023","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD007572.pub4-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"I4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"4 Part 2","key":"10.1002\/14651858.CD007572.pub4-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0016-5085(79)90385-8","article-title":"National Cooperative Crohn's Disease Study: results of drug treatment","volume":"77","author":"Summers","year":"1979","journal-title":"Gastroenterology"},{"issue":"10080","key":"10.1002\/14651858.CD007572.pub4-BIB0124|cit124","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn's disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD007572.pub4-BIB0125|cit125","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn's disease: Medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"Journal of Crohn's & Colitis"},{"issue":"5","key":"10.1002\/14651858.CD007572.pub4-BIB0126|cit126","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: An update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD007572.pub4-BIB0127|cit127","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1146\/annurev-immunol-042617-053055","article-title":"Translating immunology into therapeutic concepts for inflammatory bowel disease","volume":"36","author":"Uhlig","year":"2018","journal-title":"Annual Review of Immunology"},{"issue":"9","key":"10.1002\/14651858.CD007572.pub4-BIB0128|cit128","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1093\/ecco-jcc\/jjaa057","article-title":"Systematic review of development and content validity of patient-reported outcome measures in inflammatory bowel disease: Do we measure what we measure?","volume":"14","author":"Van Andel","year":"2020","journal-title":"Journal of Crohn's & Colitis"},{"issue":"9","key":"10.1002\/14651858.CD007572.pub4-BIB0129|cit129","doi-asserted-by":"publisher","first-page":"3702","DOI":"10.1007\/s10620-023-08014-z","article-title":"Efficacy and safety of IL-12\/23 and IL-23 inhibitors for Crohn's disease: Systematic review and meta-analysis","volume":"68","author":"Vuyyuru","year":"2023","journal-title":"Digestive Diseases and Sciences"},{"issue":"6","key":"10.1002\/14651858.CD007572.pub4-BIB0130|cit130","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.cgh.2023.12.023","article-title":"Comparative efficacy of advanced therapies for achieving endoscopic outcomes in Crohn's disease: A systematic review and network meta-analysis","volume":"22","author":"Vuyyuru","year":"2024","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD007572.pub4-BIB0131|cit131","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007572.pub2","article-title":"Anti-IL-12\/23p40 antibodies for induction of remission in Crohn's disease","author":"Khanna","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD007572.pub4-BIB0132|cit132","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007572.pub3","article-title":"Anti-IL-12\/23p40 antibodies for induction of remission in Crohn's disease","author":"MacDonald","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:25:54Z","timestamp":1786123554000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD007572.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":132,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007572.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]}}}